Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Development for the obesity indication was discontinued in 2007 as a direct result of that Phase IIb outcome
Potential Limitations and Cautions While AOD 9604s prospects seem promising, its pivotal to acknowledge potential limitations: Data on long-term safety is still in the nascent stages
TB-500 peptide is available for research and laboratory purposes only
Just be sure to follow your providers guidance to avoid imbalances [*]
doi:10.1007/BF00581375 PMID: 568769 3
US$ 21.65
US$ 20.64
US$ 22.95
US$ 25.11
US$ 26.74
US$ 22.34
